



## Senzime Annual Report 2019

**Press release: Uppsala, April 16, 2020. Senzime AB (publ) today announces that the company's Annual report for year 2019 is now available in Swedish on the company's website [www.senzime.com](http://www.senzime.com)**

**For further information, please contact:**

Pia Renaudin, CEO of Senzime AB

Tel: +46 (0)70-813 34 17, email: [pia.renaudin@senzime.com](mailto:pia.renaudin@senzime.com)

Erik Bergman, CFO

Tel: +46 (0)73-258 81 59, e-post: [erik.bergman@senzime.com](mailto:erik.bergman@senzime.com)

### **TO THE EDITORS**

#### **About Senzime**

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, [info@fnca.se](mailto:info@fnca.se) is Certified Adviser for Senzime. [www.senzime.com](http://www.senzime.com)